Bioaffinity Technologies Inc (BIAF)

$0.93 -0.15 (-13.84%)
Market Cap 4.86M
Revenue (ttm) 9.36M
Net Income (ttm) -9.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -96.58%
Debt to Equity Ratio 0.02
Volume 215,800
Avg Vol 153,750
Day's Range N/A - N/A
Shares Out 4.50M
Stochastic %K 46%
Beta 2.44
Analysts Strong Buy
Price Target $6.00

Company Profile

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, incl...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 210 698 5334
Address:
3300 Nacogdoches Road, Suite 216, San Antonio, United States
Cashflow62
Cashflow62 Feb. 23 at 8:30 PM
$BIAF Added.....
1 · Reply
Logic102
Logic102 Feb. 23 at 6:00 PM
$BIAF Buy Low Sell High.
1 · Reply
TinyTiger19
TinyTiger19 Feb. 19 at 7:25 PM
$BIAF $ATGL $UONE $AGIG /:/
0 · Reply
24MoneyBags24
24MoneyBags24 Feb. 19 at 7:16 PM
$BIAF took a small position, looks ready for a nice pop
0 · Reply
YuGi0o25
YuGi0o25 Feb. 19 at 7:04 PM
$BIAF Time to run!
0 · Reply
PennySearch
PennySearch Feb. 19 at 6:30 PM
$DRMA - 8.68x RVOL +56% 17.3M volume (2.0M avg) $1.4M market cap Day Range: 1.42 – 2.07 52W Range: 1.21 – 23.70 $BIAF - 7.86x RVOL +10% 1.5M volume (192.8K avg) $5.7M market cap Day Range: 1.17 – 1.33 52W Range: 0.69 – 46.53 $CDIO - 5.05x RVOL +15% 13.8M volume (2.7M avg) $4.5M market cap Day Range: 2.07 – 2.69 52W Range: 0.97 – 20.34 Top gainers with unusually high relative volume. Momentum + attention in one screen. Which one are you watching? 👀 PennySearch
0 · Reply
BreakoutPika
BreakoutPika Feb. 19 at 6:16 PM
$ABTC $NB $ASTI $BIAF [
0 · Reply
BreakoutPika
BreakoutPika Feb. 19 at 5:43 PM
$BINI $VOR $BIAF $LONA ∆
1 · Reply
Logic102
Logic102 Feb. 19 at 4:43 PM
$BIAF Test is the real deal, no doubt about it. My position here is small thus far mainly due to more dilution fears but the test itself is worth many millions so that's the backstop. Three words sum up the future of the company as a going entity: Sales, Sales, Sales
0 · Reply
CedarFence
CedarFence Feb. 19 at 4:26 PM
$BIAF Just my opinion - Frustrating, yes. Absolutely. But not a scam. The technology is the real deal. And will save lives. This needs to get WIDER distribution, if anything. The current methodology is just “wait and see” after observing an anomaly on a chest scan. Which means a cancer can spread. With this test, cancer can be identified instead of waiting. This test can identify lung cancer at Stage 1. Making treatment successful almost 9 out of 10 times. I’m hoping for this company to get it scaled up. I’m always going to bet for lives saved. Again - just my opinion.
0 · Reply
Latest News on BIAF
New Case Study Highlights Ability of bioAffinity Technologies' CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer

Feb 19, 2026, 11:00 AM EST - 4 days ago

New Case Study Highlights Ability of bioAffinity Technologies' CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer

Clinical Utility of bioAffinity Technologies' CyPath® Lung Test Demonstrated in Real-World Case Study

Feb 17, 2026, 8:00 AM EST - 6 days ago

Clinical Utility of bioAffinity Technologies' CyPath® Lung Test Demonstrated in Real-World Case Study

bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board

Feb 9, 2026, 8:00 AM EST - 14 days ago

bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board

bioAffinity Technologies' Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation

Jan 7, 2026, 8:00 AM EST - 6 weeks ago

bioAffinity Technologies' Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation

bioAffinity Technologies' Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable

Dec 3, 2025, 8:00 AM EST - 2 months ago

bioAffinity Technologies' Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable

bioAffinity Technologies Reports Third Quarter 2025 Financial Results

Nov 14, 2025, 8:00 AM EST - 3 months ago

bioAffinity Technologies Reports Third Quarter 2025 Financial Results

bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume

Nov 5, 2025, 8:00 AM EST - 3 months ago

bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume

bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases

Oct 28, 2025, 8:00 AM EDT - 4 months ago

bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases

bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025

Oct 20, 2025, 8:00 AM EDT - 4 months ago

bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025

bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer

Oct 16, 2025, 8:00 AM EDT - 4 months ago

bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer

bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements

Oct 15, 2025, 8:00 AM EDT - 4 months ago

bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements

WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 9, 2025, 2:00 PM EDT - 4 months ago

WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 9, 2025, 1:00 PM EDT - 4 months ago

bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 8, 2025, 4:15 PM EDT - 4 months ago

WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 8, 2025, 3:45 PM EDT - 4 months ago

bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025

Oct 7, 2025, 8:00 AM EDT - 4 months ago

bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025

WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m

Sep 30, 2025, 12:44 PM EDT - 5 months ago

WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m

bioAffinity Technologies Announces Closing of $4.8 Million Public Offering

Sep 30, 2025, 12:15 PM EDT - 5 months ago

bioAffinity Technologies Announces Closing of $4.8 Million Public Offering

WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m

Sep 29, 2025, 5:59 PM EDT - 5 months ago

WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m

bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering

Sep 29, 2025, 3:51 PM EDT - 5 months ago

bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering

bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung

Sep 26, 2025, 8:00 AM EDT - 5 months ago

bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung

bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025

Sep 17, 2025, 8:15 AM EDT - 5 months ago

bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025

Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules

Sep 9, 2025, 8:00 AM EDT - 5 months ago

Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules

bioAffinity Technologies Appoints New Members to Board of Directors

Aug 18, 2025, 8:00 AM EDT - 6 months ago

bioAffinity Technologies Appoints New Members to Board of Directors

bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

Aug 14, 2025, 4:15 PM EDT - 6 months ago

bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

bioAffinity Technologies Reports Second Quarter 2025 Results

Aug 14, 2025, 8:00 AM EDT - 6 months ago

bioAffinity Technologies Reports Second Quarter 2025 Results

bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

Aug 13, 2025, 9:25 AM EDT - 6 months ago

bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales

Aug 13, 2025, 8:00 AM EDT - 6 months ago

bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales

Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results

Jul 29, 2025, 8:00 AM EDT - 7 months ago

Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results

Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic

Jul 22, 2025, 9:00 AM EDT - 7 months ago

Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic

bioAffinity Technologies Announces Notification of China Patent Award for Company's Noninvasive Lung Cancer Diagnostic

Jul 15, 2025, 9:00 AM EDT - 7 months ago

bioAffinity Technologies Announces Notification of China Patent Award for Company's Noninvasive Lung Cancer Diagnostic

bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference

Jun 26, 2025, 9:00 AM EDT - 8 months ago

bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference

bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy

Jun 24, 2025, 9:00 AM EDT - 8 months ago

bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy

bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board

Jun 11, 2025, 9:00 AM EDT - 9 months ago

bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board

bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics

May 28, 2025, 9:00 AM EDT - 9 months ago

bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics

bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer

May 20, 2025, 9:00 AM EDT - 9 months ago

bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer

bioAffinity Technologies Reports First Quarter 2025 Results

May 15, 2025, 8:30 AM EDT - 10 months ago

bioAffinity Technologies Reports First Quarter 2025 Results

Independent White Paper Highlights Real-World Impact of bioAffinity Technologies' CyPath® Lung in Diagnosing Early-Stage Lung Cancer

May 8, 2025, 9:00 AM EDT - 10 months ago

Independent White Paper Highlights Real-World Impact of bioAffinity Technologies' CyPath® Lung in Diagnosing Early-Stage Lung Cancer

WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering

May 7, 2025, 1:15 PM EDT - 10 months ago

WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering

bioAffinity Technologies Announces Closing of $3.25 Million Offering

May 7, 2025, 1:00 PM EDT - 10 months ago

bioAffinity Technologies Announces Closing of $3.25 Million Offering

WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering

May 6, 2025, 10:30 AM EDT - 10 months ago

WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering

bioAffinity Technologies Announces Pricing of $3.25 Million Offering

May 6, 2025, 9:25 AM EDT - 10 months ago

bioAffinity Technologies Announces Pricing of $3.25 Million Offering

bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

Apr 17, 2025, 9:15 AM EDT - 11 months ago

bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024

Mar 31, 2025, 9:28 AM EDT - 11 months ago

bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024

Case Study: bioAffinity Technologies' CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

Mar 26, 2025, 9:00 AM EDT - 11 months ago

Case Study: bioAffinity Technologies' CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

Case Study: bioAffinity Technologies' Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence

Mar 19, 2025, 9:00 AM EDT - 1 year ago

Case Study: bioAffinity Technologies' Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence

Physicians' Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer

Mar 13, 2025, 9:00 AM EDT - 1 year ago

Physicians' Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer

bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

Mar 6, 2025, 8:00 AM EST - 1 year ago

bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

Feb 26, 2025, 12:10 PM EST - 1 year ago

WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

Feb 26, 2025, 11:30 AM EST - 1 year ago

bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

Cashflow62
Cashflow62 Feb. 23 at 8:30 PM
$BIAF Added.....
1 · Reply
Logic102
Logic102 Feb. 23 at 6:00 PM
$BIAF Buy Low Sell High.
1 · Reply
TinyTiger19
TinyTiger19 Feb. 19 at 7:25 PM
$BIAF $ATGL $UONE $AGIG /:/
0 · Reply
24MoneyBags24
24MoneyBags24 Feb. 19 at 7:16 PM
$BIAF took a small position, looks ready for a nice pop
0 · Reply
YuGi0o25
YuGi0o25 Feb. 19 at 7:04 PM
$BIAF Time to run!
0 · Reply
PennySearch
PennySearch Feb. 19 at 6:30 PM
$DRMA - 8.68x RVOL +56% 17.3M volume (2.0M avg) $1.4M market cap Day Range: 1.42 – 2.07 52W Range: 1.21 – 23.70 $BIAF - 7.86x RVOL +10% 1.5M volume (192.8K avg) $5.7M market cap Day Range: 1.17 – 1.33 52W Range: 0.69 – 46.53 $CDIO - 5.05x RVOL +15% 13.8M volume (2.7M avg) $4.5M market cap Day Range: 2.07 – 2.69 52W Range: 0.97 – 20.34 Top gainers with unusually high relative volume. Momentum + attention in one screen. Which one are you watching? 👀 PennySearch
0 · Reply
BreakoutPika
BreakoutPika Feb. 19 at 6:16 PM
$ABTC $NB $ASTI $BIAF [
0 · Reply
BreakoutPika
BreakoutPika Feb. 19 at 5:43 PM
$BINI $VOR $BIAF $LONA ∆
1 · Reply
Logic102
Logic102 Feb. 19 at 4:43 PM
$BIAF Test is the real deal, no doubt about it. My position here is small thus far mainly due to more dilution fears but the test itself is worth many millions so that's the backstop. Three words sum up the future of the company as a going entity: Sales, Sales, Sales
0 · Reply
CedarFence
CedarFence Feb. 19 at 4:26 PM
$BIAF Just my opinion - Frustrating, yes. Absolutely. But not a scam. The technology is the real deal. And will save lives. This needs to get WIDER distribution, if anything. The current methodology is just “wait and see” after observing an anomaly on a chest scan. Which means a cancer can spread. With this test, cancer can be identified instead of waiting. This test can identify lung cancer at Stage 1. Making treatment successful almost 9 out of 10 times. I’m hoping for this company to get it scaled up. I’m always going to bet for lives saved. Again - just my opinion.
0 · Reply
Rvazstocksfl
Rvazstocksfl Feb. 19 at 4:18 PM
$BIAF scam. Down 99 in 1 year
0 · Reply
TheTradeXchange
TheTradeXchange Feb. 19 at 4:00 PM
$BIAF New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer
0 · Reply
PennySearch
PennySearch Feb. 19 at 3:38 PM
$ENVB - 24.85x RVOL +8% 16.3M volume (656.1K avg) $1.4M market cap Day Range: 2.23 – 2.47 52W Range: 1.96 – 54.00 $CDIO - 4.12x RVOL +16% 10.8M volume (2.6M avg) $4.5M market cap Day Range: 2.31 – 2.69 52W Range: 0.97 – 20.34 $BIAF - 3.65x RVOL +10% 575.4K volume (157.4K avg) $5.7M market cap Day Range: 1.17 – 1.32 52W Range: 0.69 – 46.53 Top gainers with unusually high relative volume. Momentum + attention in one screen. Which one are you watching? 👀 PennySearch
0 · Reply
traitor4life
traitor4life Feb. 19 at 3:27 PM
$BIAF they are loading up, I am too
0 · Reply
Investing4Knowledge
Investing4Knowledge Feb. 19 at 2:40 PM
$BIAF - adding here
0 · Reply
Itinerant
Itinerant Feb. 19 at 2:37 PM
$BIAF The publicly traded warrants of BIAF are shown on Nasdaq as June 22, 2027 $8.1. This data is wrong. The true data is September 1, 2027 $90.9. (Footnote 14, 10Q) Obviously, a strike price over $90 means that the warrants are very unlikely to go into the money (unless there is a buyout). I think that the warrants have been trading at 22 cents based upon the misleading information shown on Nasdaq. I have advised the company to correct this information. I therefore expect the warrants to go to about 2 cents. JMO
0 · Reply
Cashflow62
Cashflow62 Feb. 19 at 1:01 PM
$BIAF Nice bid right now......
0 · Reply
CedarFence
CedarFence Feb. 18 at 5:39 PM
$BIAF I know. Maybe some good news from the shareholder meeting in April(?), I think. I hope it doesn’t go to a merger, but anything can happen. Regardless, these tests will save lives. I’m a fan and want to see them get a Grand Slam. Just my opinion.
1 · Reply
agarfield
agarfield Feb. 18 at 5:05 PM
$BIAF I would really like to see this team succeed, I just don't see where they get the financing without heavy dilution, but hoping for some stability there before jumping in again.
0 · Reply
TinyTiger19
TinyTiger19 Feb. 17 at 6:51 PM
$IMMX $MTC $GNTA $BIAF •<>•
0 · Reply
BreakoutPika
BreakoutPika Feb. 17 at 6:30 PM
$VOR $BIAF $LONA $ECDA e
0 · Reply
Logic102
Logic102 Feb. 17 at 6:27 PM
$MBOT $CLIR Bought the early dip on each of these beaten down very different microcap names that have a very bright 2026 ahead of them now that they are selling their disruptive technologies. It's all about the orders and sales now. I also like $BIAF and DCGO for similar reasons.
0 · Reply